

AI-Driven Protocol Review: Accelerating and Simplifying Review

Aditya Moogi, Clinical Data Insights Analyst, Novo Nordisk Service
Centre India Private Ltd, Bengaluru, India

Abstract

Clinical trials are guided by documents - protocols, plans, manuals - that are rich in knowledge but locked in static formats. As the volume and complexity of these documents grow, traditional ways of accessing and interpreting them no longer scale. This presentation explores how the clinical trial industry must shift from systems that store information to systems that understand it. By adopting a mindset of designing intelligence, we introduce a framework that leverages large language models (LLMs) and retrieval-augmented generation (RAG) to transform passive documents into interactive knowledge interfaces. This session explores how AI can be thoughtfully embedded into clinical re-search to transform protocol engagement from reading & interpreting to understanding and interacting. We present an example of this thinking, illustrating how intelligent document interaction can reduce protocol misinterpretation, improve efficiency, and empower trial teams at every level. This is not just about AI adoption – it is about redesigning how we engage with clinical knowledge itself.

Keywords: Clinical trials, Protocol management, Retrieval-Augmented Generation, Large Language Models, Artificial Intelligence, Natural Language Processing, Knowledge management, Regulatory compliance.

1. Introduction

1.1 Background and Context

Clinical trial protocols serve as the cornerstone of pharmaceutical research, providing comprehensive guidelines that govern every aspect of a clinical study. These documents typically span hundreds of pages and contain critical information ranging from patient inclusion and exclusion criteria to detailed visit schedules, dosing regimens, safety monitoring procedures, and statistical analysis plans. The

protocol ensures consistency across multiple sites, regulatory compliance, and patient safety throughout the trial lifecycle.

Despite their fundamental importance, clinical trial protocols present significant operational challenges for research teams. Study coordinators, clinical research associates, principal investigators, and other stakeholders frequently need to access specific information within protocols, often under time-sensitive circumstances. Traditional methods of information retrieval-manual reading, keyword searches in PDF documents, or maintaining separate reference guides-are inefficient, time-consuming, and prone to human error.

1.2 The Problem Statement

The current paradigm of protocol management suffers from several critical limitations that impact trial quality and efficiency. First, the static nature of protocol documents means that information remains locked in lengthy PDF files, requiring extensive manual review to extract relevant details. Research team members often spend considerable time searching through protocols just to find a single line about visit windows, eligibility requirements, or procedural details. This inefficiency multiplies across teams, sites, and studies, consuming valuable resources that could be directed toward patient care and study execution.

Second, conventional keyword searches are inadequate for complex protocol queries. Simple text matching fails to understand context, synonyms, or the relationships between different protocol sections. When a coordinator searches for "exclusion criteria for diabetic patients," a keyword search might miss relevant information described using different terminology or located in unexpected sections of the document.

Third, interpretation inconsistencies across team members can lead to protocol deviations and compliance issues. Different individuals may interpret ambiguous protocol language differently, leading to variations in study conduct across sites. This lack of standardized interpretation creates risks for data integrity and regulatory compliance.

Finally, the manual nature of protocol review creates scalability challenges. As pharmaceutical companies manage increasingly complex portfolios of clinical trials, the cumulative time spent on protocol review becomes a significant bottleneck. Organizations need systems that can scale efficiently without proportional increases in human resources.

2. Technical Architecture

2.1 Theoretical Foundation

2.1.1 Large Language Models (LLMs)

Large Language Models represent a breakthrough in artificial intelligence, capable of understanding and generating human language with remarkable fluency and contextual awareness. These models, trained on vast corpora of text data, develop sophisticated representations of language structure, semantics, and reasoning patterns. In the context of clinical trial protocols, LLMs offer the ability to interpret complex medical and regulatory language, understand the relationships between different protocol sections, and generate clear, natural language responses to user queries.

However, LLMs alone face a critical limitation. They can generate plausible-sounding but factually incorrect information, a phenomenon known as "hallucination." When asked about specific protocol details, an LLM without access to the actual document might confidently produce fabricated information that appears authoritative but contradicts the real protocol content. This limitation makes standalone LLMs unsuitable for clinical applications where accuracy and traceability are non-negotiable requirements.

2.1.2 Retrieval-Augmented Generation (RAG)

Retrieval-Augmented Generation addresses the hallucination problem by grounding LLM responses in actual source documents. RAG systems combine two powerful capabilities: information retrieval and natural language generation. When a user poses a query, the system first searches a specialized knowledge base to retrieve the most relevant passages from source documents. These retrieved passages are then provided as context to the LLM, which uses them to generate an accurate, grounded response.

The key advantage of RAG is that it transforms the LLM from a knowledge generator to a knowledge synthesizer. Rather than relying on its training data to answer questions, the LLM receives explicit, current information from the protocol and uses its language understanding capabilities to present that information clearly. This approach ensures responses are both accurate (grounded in actual protocol text) and accessible (presented in natural language that users can easily understand).

For clinical trial protocols, RAG provides an ideal solution: it maintains the interpretive and explanatory power of LLMs while ensuring every response can be

traced back to specific protocol sections, satisfying regulatory requirements for documentation and auditability.

2.2 System Architecture

2.2.1 System Overview

The AI Protocol Assistant employs a multi-stage architecture designed to transform static protocol documents into an intelligent, queryable knowledge system. The architecture comprises four primary components: document ingestion and processing, vector database storage, query processing and retrieval, and response generation with citation. Each component plays a critical role in ensuring the system delivers accurate, traceable, and user-friendly responses to protocol queries.

2.2.2 Document Ingestion and Processing Pipeline

The document processing pipeline begins when a user uploads a clinical trial protocol through a simple, intuitive interface. The system accepts protocols in common formats such as PDF or Microsoft Word, accommodating the various formats used across the pharmaceutical industry. Upon upload, the system initiates a sophisticated processing workflow designed to extract, structure, and prepare the protocol content for semantic search.

The first step involves text extraction, where the system parses the document to extract all textual content while preserving metadata such as page numbers, section headings, and document structure. This metadata preservation is crucial for later citation and traceability. The extraction process handles complex document formatting, including tables, figures, and multi-column layouts, ensuring no critical information is lost.

Following extraction, the system performs intelligent chunking, dividing the protocol into meaningful segments. Unlike simple fixed-length chunking, the system employs semantic chunking that respects document structure, keeping related information together. For example, an eligibility criterion and its associated rationale remain in the same chunk, ensuring context is preserved. Chunk sizes are optimized to balance detail (chunks must contain sufficient context) with precision (chunks must be focused enough to avoid retrieving irrelevant information).

Each chunk is then processed through an embedding model, a neural network that converts text into high-dimensional vector representations. These embeddings capture semantic meaning—chunks discussing similar concepts will have similar vector representations, even if they use different terminology. This semantic representation enables the system to understand that a query about "diabetic

patients" should retrieve chunks mentioning "diabetes mellitus" or "elevated glucose levels," even if the exact phrase doesn't appear.

2.2.3 Vector Database Storage

The processed chunks and their embeddings are stored in a specialized vector database optimized for similarity search. Unlike traditional relational databases that retrieve records based on exact matches, vector databases excel at finding semantically similar content through nearest-neighbor search in high-dimensional space. When presented with a query embedding, the database rapidly identifies the chunks with the most similar vector representations, effectively finding protocol sections that discuss concepts related to the query.

The vector database maintains not only the embeddings but also the original text chunks and their associated metadata (page numbers, section titles, document identifiers). This dual storage ensures that when relevant chunks are retrieved, the system can both present the actual protocol text to users and provide precise citations. The database architecture supports rapid ingestion of new protocols and can scale to accommodate thousands of documents across multiple trials and therapeutic areas.

2.2.4 Query Processing and Semantic Retrieval

When a user submits a query in natural language-such as "What are the exclusion criteria for patients with renal impairment in Arm B?"-the system initiates a sophisticated retrieval process. The query is first processed through the same embedding model used for protocol chunks, converting the question into a vector representation that captures its semantic intent.

This query embedding is then used to search the vector database, identifying the most semantically relevant protocol sections. The system typically retrieves the top 3-5 most relevant chunks, balancing the need for comprehensive context with the constraint of providing focused, manageable information to the LLM. The retrieval process employs advanced techniques such as maximum marginal relevance to ensure retrieved chunks are both relevant to the query and diverse from each other, avoiding redundancy.

Importantly, the retrieval process is transparent and auditable. Each retrieved chunk includes its source location (page number, section), enabling complete traceability from the final response back to the original protocol document. This transparency is essential for regulatory compliance and building user trust in the system's responses.

2.2.5 Response Generation with Citation

Once relevant protocol sections are retrieved, the system constructs a prompt for the LLM that includes both the user's query and the retrieved context. The prompt is carefully engineered to instruct the LLM to answer based solely on the provided protocol excerpts, to cite specific page numbers, and to acknowledge when retrieved information is insufficient to fully answer the query.

The LLM processes this prompt and generates a response that synthesizes information from the retrieved chunks, presenting it in clear, accessible language. The response includes explicit citations to specific protocol pages, allowing users to verify the information and explore the full context if needed. For example, a response might state: "According to the protocol (page 23), patients with severe renal impairment ($\text{CrCl} < 30 \text{ mL/min}$) are excluded from Arm B. Additional renal-related exclusions are detailed on page 24."

The system implements multiple safeguards against hallucination. By grounding responses in retrieved text, explicitly instructing the LLM to cite sources, and limiting responses to information present in the protocol, the architecture ensures accuracy while maintaining the natural language fluency that makes the system accessible to users.

2.3 Technical Implementation Details

2.3.1 Technology Stack

The AI Protocol Assistant is built on a modern, scalable technology stack selected for performance, reliability, and maintainability. Key components include:

- **Embedding Models:** State-of-the-art sentence transformer models specifically fine-tuned for biomedical and clinical text, ensuring accurate semantic representation of medical terminology and concepts.
- **Vector Database:** High-performance vector storage systems providing millisecond-scale similarity search across millions of document chunks.
- **Large Language Model:** Integration with leading LLM APIs selected for their strong performance on technical and medical text comprehension.
- **Application Framework:** Web-based interface built with modern frameworks providing intuitive user experience and robust API endpoints for integration with existing clinical systems.

2.3.2 Performance Optimization

The system implements multiple optimization strategies to ensure responsive performance even with large protocol documents. Caching mechanisms store frequently accessed information, reducing redundant computation. Asynchronous processing handles document ingestion in the background, allowing users to continue working while protocols are being indexed. The vector database employs approximate nearest neighbor search algorithms that trade minimal accuracy for substantial speed improvements, delivering results in tens of milliseconds rather than seconds.

2.3.3 Security and Compliance

Given the sensitive nature of clinical trial protocols, the system implements comprehensive security measures including end-to-end encryption, role-based access controls, and complete audit logging. All protocol documents are stored in compliance with regulatory requirements for electronic records, and the system supports 21 CFR Part 11 compliance for organizations requiring FDA-validated electronic systems. User authentication integrates with enterprise identity management systems, and all interactions are logged for compliance monitoring and audit trail purposes.

3. Applications and Use Cases

3.1 Primary Use Cases

3.1.1 Study Coordinator Support

Study coordinators face time-sensitive questions about patient eligibility, visit windows, medication restrictions, and procedures. The AI Protocol Assistant instantly retrieves relevant protocol sections with citations, reducing query resolution time from 10-15 minutes to seconds. Example query: "What are the inclusion and exclusion criteria?" receives immediate, cited responses enabling real-time decision-making during patient interactions.

3.1.2 Clinical Research Associate (CRA) Monitoring

CRAs conducting site monitoring visits require rapid protocol verification during source data review. The system enables instant confirmation of visit schedules, procedure timing, dose modifications, and safety requirements. Query example: "What is the acceptable timing window for Week 12 safety labs?" Citation features support documentation of monitoring findings, allowing CRAs to reference specific protocol pages in reports and site queries, dramatically improving monitoring efficiency and accuracy.

3.1.3 New Staff Onboarding and Training

New team members use the assistant as an always-available training resource, exploring protocol details independently rather than interrupting experienced colleagues. The natural language interface accommodates users regardless of medical terminology familiarity. Simple queries like "What happens at the first visit?" receive comprehensive, step-by-step overviews with protocol references, accelerating competency development and reducing senior staff training burden.

3.1.4 Protocol Amendment Impact Assessment

The system handles multiple protocol versions, enabling rapid amendment impact assessment. Users query version-specific changes ("What changed in exclusion criteria between version 2.0 and 3.0?") to quickly understand implications for ongoing activities and plan necessary retraining or procedural updates.

3.2 Secondary Applications and Future Extensions

3.2.1 Multi-Document Knowledge Base

The RAG architecture extends beyond protocols to encompass Statistical Analysis Plans (SAPs), Case Report Forms (CRFs), Informed Consent Forms, Study Reference Manuals, and Laboratory Manuals. This multi-document capability transforms the system into a complete trial knowledge platform. Users query across documents ("What safety assessments from the protocol are captured on which CRF pages?") receiving integrated responses that synthesize information across sources, significantly reducing documentation fragmentation.

3.2.2 Integration with Clinical Trial Management Systems

Future integration with Clinical Trial Management Systems (CTMS) and Electronic Data Capture (EDC) platforms will enable contextual protocol assistance within operational workflows. When coordinators open patient visits in EDC systems, the assistant proactively displays relevant protocol requirements or allows in-application queries. API-based integration embeds protocol intelligence throughout the clinical technology ecosystem, providing guidance at decision points to prevent protocol deviations before they occur.

3.2.3 Intelligent Protocol Authoring Support

The same AI technology supporting protocol queries can assist authors during document creation. By analyzing successful protocols and therapeutic area standards, the system suggests protocol language, identifies ambiguous sections,

flags inconsistencies, and recommends clearer phrasing-shifting from information retrieval to proactive quality improvement in protocol development.

3.2.4 Multilingual Support for Global Trials

The system extends to support multilingual queries and responses, allowing site staff to query protocols in native languages while accessing English-language documents. Semantic understanding enables accurate cross-language interpretation, reducing language barriers and enhancing accessibility for non-English-speaking sites in global trials.

3.3 Measurable Benefits and Impact

3.3.1 Efficiency Gains

Implementations demonstrate 70-80% reduction in protocol review time, with complex queries answered in under 30 seconds versus 15-20 minutes manually. This translates to dozens of hours saved weekly per site, allowing staff to focus on patient care. Junior team members find answers independently, reducing interruptions for senior staff and effectively scaling institutional knowledge across organizations.

3.3.2 Quality and Compliance Improvements

Standardized responses ensure consistent protocol interpretation across teams, minimizing deviations from inconsistent understanding. Complete citation traceability supports regulatory inspections and quality assurance reviews. Organizations report reduced protocol deviation rates, attributing improvements to better protocol understanding and accessible accurate information at decision points. Audit logs document protocol-related questions and decisions for quality investigations.

3.3.3 Scalability and Cost Reduction

The system democratizes protocol expertise, allowing unlimited simultaneous users to access high-quality information without bottlenecks. As organizations expand trial portfolios, traditional reliance on limited protocol experts becomes strained. AI-powered scalability enables support for more trials and sites without proportional increases in expert staff, directly reducing operational costs while maintaining quality standards.

4. Conclusion

4.1 Summary of Key Findings

This research demonstrates that the integration of Retrieval-Augmented Generation and Large Language Models successfully addresses longstanding inefficiencies in clinical trial protocol management. The AI Protocol Assistant transforms static, complex protocol documents into dynamic, intelligent knowledge systems that provide instant, accurate, and traceable responses to natural language queries. By combining the semantic understanding of LLMs with the grounding effect of RAG, the system eliminates the hallucination risks that would otherwise make AI unsuitable for regulatory environments while delivering the accessibility and intelligence users need.

The technical architecture presented-encompassing document processing, vector embedding, semantic retrieval, and cited response generation-provides a robust, scalable foundation for protocol intelligence. Implementation across multiple use cases validates the system's practical utility, demonstrating significant time savings, improved protocol compliance, enhanced team alignment, and better regulatory readiness. The framework extends naturally beyond protocols to encompass comprehensive clinical documentation, establishing a path toward true AI-driven knowledge ecosystems for clinical research.

4.2 Implications for Clinical Research

The broader implications of this work extend beyond operational efficiency. By fundamentally changing how research teams interact with clinical knowledge, the AI Protocol Assistant represents a paradigm shift in clinical trial operations. Protocols need no longer be static documents that gate access to information; they can become interactive, intelligent resources that actively support decision-making and operational excellence.

This transformation has important implications for trial quality and patient safety. When protocol requirements are more accessible and consistently interpreted, protocol deviations decrease, data quality improves, and patient safety is enhanced. When research staff spend less time searching documents and more time on patient-facing activities, the entire trial experience improves for participants. The cumulative effect of these improvements accelerates drug development timelines, potentially bringing beneficial treatments to patients faster.

From an organizational perspective, the technology enables new operational models. Research organizations can distribute protocol expertise more effectively, support larger trial portfolios with the same staff resources, and make protocol knowledge accessible to a broader range of stakeholders including patients and caregivers. This democratization of clinical knowledge aligns with broader trends toward patient-centricity and operational efficiency in clinical research.

4.3 Limitations and Considerations

Despite the significant benefits demonstrated, important limitations and considerations must be acknowledged. First, the system's effectiveness depends critically on protocol quality. Ambiguous or inconsistent protocol language will produce ambiguous responses, regardless of AI sophistication. Organizations implementing such systems should view them as complements to, not replacements for, high-quality protocol development and human expertise.

Second, while the RAG architecture substantially reduces hallucination risks, it does not eliminate them entirely. LLMs can still occasionally misinterpret retrieved text or make connections not explicitly present in the protocol. Robust validation, continuous monitoring, and clear communication to users that responses should be verified for critical decisions remain essential safeguards.

Third, regulatory acceptance of AI-assisted protocol interpretation may vary across jurisdictions and regulatory agencies. Organizations must work proactively with regulators to establish validation frameworks and demonstrate the reliability of AI-generated responses. The complete traceability and citation features of the system facilitate this validation, but regulatory dialogue remains important.

Finally, successful implementation requires thoughtful change management. Research staff accustomed to traditional protocol review methods may initially be skeptical of AI assistance. Organizations must invest in training, clearly communicate the system's capabilities and limitations, and build confidence through demonstrated accuracy and reliability. The technology succeeds best when positioned as a tool that augments rather than replaces human judgment.

4.4 Future Directions

Several promising research directions emerge from this work:

- Enhanced semantic understanding through fine-tuning LLMs specifically on clinical trial protocols and regulatory documents, potentially improving accuracy and domain-specific comprehension.

- Proactive intelligence that anticipates user needs, identifying potential protocol ambiguities or inconsistencies during authoring, suggesting clarifications, or alerting teams to protocol sections requiring attention during specific study phases.
- Cross-trial learning where AI systems analyze patterns across multiple trials to identify best practices, common pitfalls, and therapeutic area-specific insights that can inform future protocol development and execution.
- Integration with real-world evidence and external data sources, allowing protocol assistants to contextualize protocol requirements with current medical standards, drug interactions databases, or emerging safety signals.
- Multimodal capabilities that process not just text but also protocol tables, figures, and flow diagrams, providing more comprehensive understanding of complex study designs.

4.5 Conclusion

The AI Protocol Assistant represents more than a technological innovation, it embodies a fundamental reconceptualization of how clinical research organizations manage and leverage knowledge. By transforming protocols from static documents into dynamic, intelligent resources, this work challenges the industry to rethink long-standing assumptions about documentation, training, and operational models.

The question facing the clinical research community is not whether to adopt AI-driven knowledge management, but how to do so thoughtfully, effectively, and ethically. Organizations that successfully integrate these technologies while maintaining appropriate human oversight, regulatory compliance, and quality standards will gain substantial competitive advantages in trial execution speed, quality, and cost efficiency.

More importantly, by making trials faster, more efficient, and less error-prone, these technologies ultimately serve patients, the true beneficiaries of clinical research. When research teams can access protocol knowledge instantly, when protocol deviations decrease, and when trials execute more efficiently, beneficial treatments reach patients faster. This patient-centric outcome represents the most compelling justification for embedding intelligence into clinical trial processes.

As we stand at the threshold of widespread AI integration in clinical research, the AI Protocol Assistant demonstrates what becomes possible when we move beyond viewing documents as static repositories and instead embrace them as the foundation for intelligent, responsive systems that actively support the critical work

of bringing new medicines to patients. The future of clinical trials is not just faster or cheaper-it is fundamentally smarter, more connected, and more capable of realizing the promise of precision medicine and patient-centered care.

5. References

1. Lewis, P., Perez, E., Piktus, A., et al. (2020). Retrieval-Augmented Generation for Knowledge-Intensive NLP Tasks. *Advances in Neural Information Processing Systems*, 33, 9459-9474.
2. Brown, T., Mann, B., Ryder, N., et al. (2020). Language Models are Few-Shot Learners. *Advances in Neural Information Processing Systems*, 33, 1877-1901.
3. Reimers, N., & Gurevych, I. (2019). Sentence-BERT: Sentence Embeddings using Siamese BERT-Networks. *Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing*, 3982-3992.
4. Lee, J., Yoon, W., Kim, S., et al. (2020). BioBERT: a pre-trained biomedical language representation model for biomedical text mining. *Bioinformatics*, 36(4), 1234-1240.
5. Guu, K., Lee, K., Tung, Z., et al. (2020). REALM: Retrieval-Augmented Language Model Pre-Training. *Proceedings of the 37th International Conference on Machine Learning*, 3929-3938.
6. Johnson, A.E., Pollard, T.J., Shen, L., et al. (2016). MIMIC-III, a freely accessible critical care database. *Scientific Data*, 3, 160035.
7. Izacard, G., & Grave, E. (2021). Leveraging Passage Retrieval with Generative Models for Open Domain Question Answering. *Proceedings of the 16th Conference of the European Chapter of the ACL*, 874-880.
8. Singhal, K., Azizi, S., Tu, T., et al. (2023). Large language models encode clinical knowledge. *Nature*, 620, 172-180.
9. FDA. (2018). Electronic Source Data in Clinical Investigations. *Guidance for Industry*. U.S. Food and Drug Administration.
10. Mani, S., Chen, Y., Elasy, T., et al. (2012). Type 2 Diabetes Risk Forecasting from EMR Data using Machine Learning. *AMIA Annual Symposium Proceedings*, 2012, 606-615.
11. Khosravi, P., Kazemi, E., Imielinski, M., et al. (2018). Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images. *EBioMedicine*, 27, 317-328.

12. Ram, O., Levine, Y., Dalmedigos, I., et al. (2023). In-Context Retrieval-Augmented Language Models. *Transactions of the Association for Computational Linguistics*, 11, 1316-1331.

6. CONTACT INFORMATION

Your comments and questions are valued and encouraged. Contact the author at:

Author Name: Aditya Moogi

Company: Novo Nordisk Service Centre India Private Ltd

Address: CIGNUS 1, Plot No 75 , EPIP Area, next to SRI SATHYA SAI SUPER SPECIALITY HOSPITAL, KIADB Export Promotion Industrial Area, Whitefield, Bengaluru, Karnataka 560066

Work Phone: 7795108002

Email: IMG1@novonordisk.com

Website: [Novo Nordisk India](#)

Disclaimer: The poster does not contain any proprietary or confidential information from Novo Nordisk. The views and opinions expressed are solely those of the presenter and not of Novo Nordisk.